Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExelixisFRA:EX9 +3.50%90 EV-to-OCF is 10.87 as of Aug. 20, 2026, which is 30% below its 10-year median of 15.52. GuruFocus rates FRA:EX9 with a GF Score™ of 90/100 and a GF Value™ of €40.66 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Exelixis ranks worse than 83.53% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Exelixis's Enterprise Value is €11,060 Mil.
Exelixis's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €1,017 Mil. Therefore, Exelixis's EV-to-OCF for today is 10.87.
The historical rank and industry rank for Exelixis's EV-to-OCF or its related term are showing as below:
FRA:EX9'
s EV-to-OCF Range Over the Past 10 Years
Min: 7.53 Med: 15.52 Max: 57.58
Current: 10.82
During the past 13 years, the highest EV-to-OCF of Exelixis was 57.58. The lowest was 7.53. And the median was 15.52.
FRA:EX9's EV-to-OCF is ranked worse than 83.53% of 1409
companies
in the Biotechnology industry
Industry Median: -3.66
vs FRA:EX9: 10.82
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Exelixis's share price for today is €46.16.
Exelixis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.735.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Exelixis EV-to-OCF Related Terms
Exelixis EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Exelixis's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Exelixis's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exelixis EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exelixis's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Exelixis's EV-to-OCF falls into.
Exelixis's current Enterprise Value is €11,060 Mil.
Exelixis's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,017 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis (FRA:EX9) has a EV-to-OCF of 10.87 as of Aug. 20, 2026. This is 30% below median its historical median of 15.52. Over the past decade, Exelixis' EV-to-OCF has ranged from 7.53 to 57.58. According to the industry distribution chart, Exelixis ranks #1177 out of 1409 companies in the Biotechnology industry, placing it in the top 83.5%.
Is Exelixis' EV-to-OCF too high?
Exelixis' current EV-to-OCF of 10.87 is 30% below median its 10-year median of 15.52. Over the past 10 years, this metric has ranged from a low of 7.53 to a high of 57.58. Based on the distribution chart, Exelixis ranks #1177 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Exelixis has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' EV-to-OCF compare to MDGL and AXSM?
According to the Biotechnology industry distribution chart, Exelixis ranks #1177 out of 1409 companies for EV-to-OCF. This places Exelixis in the lower half of its industry. Historically, Exelixis' own EV-to-OCF has ranged from 7.53 to 57.58 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Exelixis's current EV-to-OCF is 10.87, which is 30% below median its own 10-year median of 15.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (FRA:EX9) is currently considered Modestly Overvalued. The stock's GF Value™ is €40.66, compared to a current price of €46.16 — trading 13.5% above its estimated fair value. The current EV-to-OCF is 10.87, which is 30% below median its 10-year median of 15.52. Exelixis' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Exelixis (FRA:EX9), the current EV-to-OCF is 10.87 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exelixis (FRA:EX9) Overvalued in 2026?
Based on GuruFocus' analysis, Exelixis stock appears to be overvalued.
The current stock price of €46.16 is trading 13.5% above its estimated GF Value™ of €40.66.
GuruFocus considers Exelixis to be Modestly Overvalued.
Key valuation signals for FRA:EX9:
EV-to-OCF: 10.87 (30% below median its 10-year median of 15.52)
GF Value™: €40.66 vs. price of €46.16 (13.5% above fair value)
No single metric tells the full story. See the FRA:EX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
90GF Score
Get the complete analysis for FRA:EX9
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EX9 has been successfully added to your 
